Fresh Tracks Therapeutics Management

Management Kriterienprüfungen 2/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Bert Marchio

Geschäftsführender

US$254.8k

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	3.8yrs
Eigentum des Geschäftsführers	n/a
Durchschnittliche Amtszeit des Managements	2.9yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	2.7yrs

Jüngste Management Updates

Recent updates

Brickell Biotech changes name to Fresh Tracks Therapeutics

Sep 07

Brickell Biotech GAAP EPS of -$0.01 beats by $1.43, revenue of $4.32M beats by $1.18M

Aug 11

Brickell Biotech completes patient enrollment in late-stage sweat disorder study

Apr 27

Brickell Biotech's(NASDAQ:BBI) Share Price Is Down 16% Over The Past Year.

Jan 06

Brickell Biotech (BBI) Investor Presentation - Slideshow

Dec 02

Brickell Bio to launch sofpironium bromide gel, 5% in Japan on November 26

Nov 18

Geschäftsführer

Bert Marchio (72 yo)

3.8yrs

Amtszeit

US$254,834

Vergütung

Mr. Albert Nicholas Marchio, II, also known as Bert, was Interim CFO & Principal Accounting Officer of NexImmune, Inc. from April 16, 2024 to August 27, 2024. He serves as Chief Financial Officer at Fresh...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Albert Marchio	CEO, CFO	3.8yrs	US$254.83k	keine Daten
Aron Aizenstat	Vice President of Corporate Development & Operations	no data	keine Daten	keine Daten
Aaron Fox-Collis	VP of Finance & Chief Accounting Officer	1.7yrs	keine Daten	keine Daten
Sue Fattor	Head of Human Resource	3.4yrs	keine Daten	keine Daten
James McElvain	Interim Head of CMC Development	2.4yrs	keine Daten	keine Daten

2.9yrs

Durchschnittliche Betriebszugehörigkeit

Erfahrenes Management: FRTXDas Führungsteam des Unternehmens gilt als erfahren (2.7 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Albert Marchio	CEO, CFO	less than a year	US$254.83k	keine Daten
Katherine Fitzgerald	Member of Scientific Advisory Board	2.7yrs	keine Daten	keine Daten
Peter Nigrovic	Member of Scientific Advisory Board	2.7yrs	keine Daten	keine Daten
Pui Lee	Member of Scientific Advisory Board	2.7yrs	keine Daten	keine Daten
Bernard Khor	Member of Scientific Advisory Board	2.7yrs	keine Daten	keine Daten
Bridget Wagner	Member of Scientific Advisory Board	2.7yrs	keine Daten	keine Daten

2.7yrs

Durchschnittliche Betriebszugehörigkeit

Erfahrener Vorstand: FRTXDie Vorstandsmitglieder gelten nicht als erfahren ( 2.4 Jahre durchschnittliche Amtszeit), was auf einen neuen Vorstand hindeutet.

Fresh Tracks Therapeutics Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Fresh Tracks Therapeutics, Inc. Announces Executive Changes

Fresh Tracks Therapeutics, Inc. Announces Resignation of Robert B. Brown from the Board of Directors, Effective Immediately

Fresh Tracks Therapeutics, Inc. Announces Executive Changes, Effective February 1, 2023

Insufficient new directors

Fresh Tracks Therapeutics Appoints Deepak Chadha to the Additional Position of Chief Operating Officer

Insufficient new directors

Recent updates

Fresh Tracks Therapeutics, Inc. Files Form 15

Fresh Tracks Therapeutics, Inc.(OTCPK:FRTX) dropped from S&P TMI Index

Fresh Tracks Therapeutics, Inc.(OTCPK:FRTX) dropped from NASDAQ Composite Index

Fresh Tracks Therapeutics Announces Its Common Stock to Be Suspended from Trading on Nasdaq At Open of Business on December 19, 2023

Fresh Tracks Therapeutics' Common Stock To Be Delisted from Nasdaq

Fresh Tracks Therapeutics' Common Stock To Be Delisted from Nasdaq

Fresh Tracks Therapeutics, Inc. Announces Executive Changes

New minor risk - Revenue size

Second quarter 2023 earnings released: US$0.39 loss per share (vs US$0.43 loss in 2Q 2022)

Fresh Tracks Therapeutics, Inc. Announces Resignation of Robert B. Brown from the Board of Directors, Effective Immediately

First quarter 2023 earnings released: US$1.14 loss per share (vs US$3.55 loss in 1Q 2022)

Full year 2022 earnings released: US$7.52 loss per share (vs US$22.12 loss in FY 2021)

Fresh Tracks Therapeutics, Inc. Announces Executive Changes, Effective February 1, 2023

Fresh Tracks Therapeutics, Inc. Announces Publication of Preclinical Data for FRTX-02

Price target increased to US$72.50

Consensus forecasts updated

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insufficient new directors

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Fresh Tracks Therapeutics, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Consensus estimates of losses per share improve by 25%

Fresh Tracks Therapeutics Appoints Deepak Chadha to the Additional Position of Chief Operating Officer

Fresh Tracks Therapeutics Initiates Multiple Ascending Dose Portion of Phase 1 Study of Dyrk1a Inhibitor FRTX-02

Brickell Biotech changes name to Fresh Tracks Therapeutics

Insufficient new directors

Brickell Biotech Receives Notice from the Nasdaq Stock Market in Relation to Non-Compliance with the Independent Director and Audit Committee Requirements

Consensus revenue estimates increase by 26%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Brickell Biotech GAAP EPS of -$0.01 beats by $1.43, revenue of $4.32M beats by $1.18M

Brickell Biotech, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Brickell Biotech, Inc. Announces Resignation of Dennison T. Veru from the Board of Directors

Brickell Biotech Regains Compliance with Nasdaq Minimum Bid Price Requirement

Brickell Biotech regains Nasdaq compliance for minimum bid price requirement

Brickell Biotech Receives a Notice from the Listing Qualifications Department of the Nasdaq Stock Market

Brickell Biotech, Inc. Announces Executive Changes

Brickell Biotech Doses First Subject in Phase 1 Study of DYRK1A Inhibitor BBI-02

Consensus revenue estimates increase by 159%

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Brickell Biotech, Inc. to Report Q1, 2022 Results on May 12, 2022

Consensus revenue estimates fall by 47%

Price target decreased to US$2.67

Full year 2021 earnings: EPS and revenues miss analyst expectations

Here's Why Brickell Biotech (NASDAQ:BBI) Must Use Its Cash Wisely

Third quarter 2021 earnings released: US$0.16 loss per share (vs US$0.15 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.16 loss per share (vs US$0.43 loss in 2Q 2020)

Co-Founder & Chairman of the Board recently bought US$134k worth of stock

Brickell Biotech, Inc. has completed a Follow-on Equity Offering in the amount of $7 million.

Brickell Biotech, Inc. Announces Final Patient Completed in First U.S. Phase 3 Pivotal Clinical Study and Patient Enrollment Completed in Second U.S. Phase 3 Pivotal Clinical Study of Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis

Brickell Biotech Announces Initiation of A Phase 1 Study of Sofpironium Bromide Gel in Primary Palmoplantar Hyperhidrosis Patients by Its Development Partner, Kaken Pharmaceutical in Japan

Brickell Biotech Receives A Notice from Listing Qualifications Department of Nasdaq Stock Market

Brickell Biotech, Inc. Announces Publication of Japan Phase 3 Long-Term Safety and Efficacy Study Results for Sofpironium Bromide Gel, 5% (ECCLOCK®) in the Journal of Dermatology

First quarter 2021 earnings released: US$0.15 loss per share (vs US$0.45 loss in 1Q 2020)

Brickell Biotech Advances To Phase III As It Eyes Commercialization

Brickell Biotech Completes Patient Enrollment in U.S. Phase 3 Pivotal Cardigan I Study of Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis

Brickell Biotech completes patient enrollment in late-stage sweat disorder study

CEO & Director recently bought US$118k worth of stock

Brickell Biotech, Inc., Annual General Meeting, Apr 19, 2021

Full year 2020 earnings released: US$0.85 loss per share (vs US$4.50 loss in FY 2019)

Earnings beat expectations, revenue disappoints

Brickell Biotech, Inc. to Report Q4, 2020 Results on Mar 09, 2021

New 90-day high: US$1.38

New 90-day high: US$1.29

Brickell Biotech, Inc. Announces Publication of Japan Pivotal Phase 3 Study Results for Sofpironium Bromide Gel, 5% (Ecclock®)

Brickell Biotech's(NASDAQ:BBI) Share Price Is Down 16% Over The Past Year.

New 90-day high: US$1.22

Brickell Biotech, Inc. Doses First Patient in Second U.S. Pivotal Phase 3 Clinical Study

Brickell Biotech (BBI) Investor Presentation - Slideshow

Brickell Biotech, Inc. Announces Management Changes

Brickell Bio to launch sofpironium bromide gel, 5% in Japan on November 26